A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial of Topical Allstate in the Prevention of the Signs and Symptoms of the Acute Response to Nasal Allergen Challenge (CETALY0001)

University of Chicago1 site in 1 countryNovember 2011

ConditionsAllergic Rhinitis

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Allergic Rhinitis
Sponsor: University of Chicago
Locations: 1
Primary Endpoint: Number of sneezes and total nasal symptom score (TNSS) (sum of nasal stuffiness, nasal discharge, and nasal itching) (scale 0-3 for each symptom; total score 0-9) are co-primary endpoints.
Status: Withdrawn
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to see whether Allstate Nasal Spray when given in the nose is safe and can reduce the signs and symptoms of allergic rhinitis (hayfever).

Registry

clinicaltrials.gov

Start Date

November 2011

End Date

April 2012

Last Updated

12 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

University of Chicago

Responsible Party

Principal Investigator

Robert Naclerio

Professor

University of Chicago

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

Number of sneezes and total nasal symptom score (TNSS) (sum of nasal stuffiness, nasal discharge, and nasal itching) (scale 0-3 for each symptom; total score 0-9) are co-primary endpoints.

Time Frame: 10 minutes following each nasal challenge